Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 17, 2026ESMO OpenOpen Access

Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRocio García‐CarboneroGCGregory M. CotéACA. Le Cesne

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

García‐Carbonero et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6635f706d05830e4c3ahttps://doi.org/10.1016/j.esmoop.2026.108534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 127O Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)2024
  2. 2Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.2026
  3. 3Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors2025 · 3 citations
  4. 4Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors2026
  5. 5A phase I/II study of nanoliposomal irinotecan and carboplatin in patients with advanced or metastatic, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma characterized by tissue and liquid next-generation sequencing.2024